ClinicalTrials.gg
CompletedNCT00800540Updated Mar 22, 2013Results posted

Circadian Ocular Perfusion Pressure and Ocular Blood Flow

A Phase 4 interventional study of Brinzolamide 10 mg/ml/Timolol 5 mg/ml eye drops suspension and Brimonidine 20 mg/ml/Timolol 5 mg/ml eye drops solution in Glaucoma, sponsored by Alcon Research. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-03-22.

Sponsored by Alcon Research (part of Alcon) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
35
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing brinzolamide in Glaucoma — none open to participants now, none under way, none of them phase 3. brinzolamide · Glaucoma.

Enrollment
17th of 21
35 · median 112
Started
2009
with 1 other
Phase 4
13 of 21
none open now
Registered
8th of 21
by date
Lead sponsor
14 of 21
Alcon Research

Among the 21 studies testing brinzolamide in Glaucoma, this one is the 17th largest by enrollment, is one of 2 that started in 2009, is one of 13 in phase 4, and was the 8th registered.

Glaucoma

1,419 studies on the registry are indexed under Glaucoma; 220 are open to participants now.

Browse Glaucoma studies →

Open to participants now

None of the 21 studies testing brinzolamide in Glaucoma is open now. The open studies under Glaucoma, anywhere →

About brinzolamide

brinzolamide: first FDA approval 1998 (AZOPT), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 154 Glaucoma studies recruiting now, 112 (73%) set no upper age limit and 9 (6%) stop at 75 or younger; 13 take children under 18; 44 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 21 studies testing brinzolamide in Glaucoma as a file.
02

Study summary

The purpose of this study was to compare the short term effects of two intraocular pressure (IOP) lowering medications on ocular perfusion pressure (OPP), ocular blood flow, intraocular pressure, and blood pressure in patients with glaucoma. Ocular perfusion pressure (OPP) is defined as the difference between arterial blood pressure (diastolic and systolic) and intraocular pressure. The primary efficacy assessment is based on diastolic ocular perfusion pressure.

03

Conditions studied

  • Glaucoma

Browse trials for

Keywords

  • glaucoma
  • ocular perfusion pressure
  • ocular blood flow
  • open angle glaucoma requiring more than one IOP-lowering medication
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Sign .
  • Diagnosis of open-angle glaucoma in at least one eye.
  • Requires more than one IOP-lowering medication.
  • IOP measurements at Screening, Safety, and Eligibility/Period 1 Baseline Visits as specified in protocol.
  • Able to discontinue all IOP-lowering medication prior to Eligibility Visit and for 4 weeks between treatment periods.
  • Willing to complete all required study visits.
  • Other protocol-defined inclusion criteria may apply.

Exclusion criteria

Exclusion Criteria:

  • Female of if pregnant, lactating, or not using highly effective measures.
  • Severe central visual field loss in either eye.
  • Previous glaucoma surgery in the study eye.
  • Intraocular surgery in the study eye within 3 months prior to the Screening Visit.
  • Wears contact lenses.
  • Allergy/ to study medication.
  • Cannot safely discontinue use of medication.
  • Uses medication that could affect IOP or blood pressure.
  • Recent use of high-dose aspirin.
  • Bronchial asthma or severe .
  • Diabetic retinopathy.
  • Any abnormality preventing reliable tonometry.
  • Any severe illness or condition unsuitable for the study, in the opinion of the investigator.
  • Other protocol-defined exclusion criteria may apply.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
35 participants (actual)

Study arms

  • Other
    AZARGA/COMBIGAN

    AZARGA, followed by COMBIGAN, as randomized. Each fixed combination instilled in the study eye, one drop twice daily (9:00 and 21:00), for six weeks, with a 4-week washout period separating the two treatment periods.

    Drug: Brinzolamide 10 mg/ml/Timolol 5 mg/ml eye drops suspension · Drug: Brimonidine 20 mg/ml/Timolol 5 mg/ml eye drops solution

  • Other
    COMBIGAN/AZARGA

    COMBIGAN, followed by AZARGA, as randomized. Each fixed combination instilled in the study eye, one drop twice daily (9:00 and 21:00), for six weeks, with a 4-week washout period separating the two treatment periods.

    Drug: Brinzolamide 10 mg/ml/Timolol 5 mg/ml eye drops suspension · Drug: Brimonidine 20 mg/ml/Timolol 5 mg/ml eye drops solution

Interventions

  • DrugBrinzolamide 10 mg/ml/Timolol 5 mg/ml eye drops suspension

    Drug page: Brinzolamide

    Fixed combination ophthalmic suspension

    Also known as: AZARGA™

  • DrugBrimonidine 20 mg/ml/Timolol 5 mg/ml eye drops solution

    Drug page: Brimonidine

    Fixed combination ophthalmic solution

    Also known as: COMBIGAN®

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline in Overall Diastolic Ocular Perfusion Pressure at Week 6

    Diastolic ocular perfusion pressure (DOPP) is defined as the difference between diastolic arterial pressure and intraocular pressure. Diastolic arterial pressure was measured with a calibrated automated sphygmomanometer. Intraocular pressure was measured with a calibrated pneumatonometer. A lower DOPP indicates a lower optic blood supply, which can be a risk factor for developing glaucoma or glaucoma progression (leading to optic nerve damage).

    Time frame: Week 0, Week 6 (period-based)

Secondary outcomes

  1. Mean Change From Baseline in Circadian Diastolic Ocular Perfusion Pressure at Week 6

    Circadian diastolic ocular perfusion pressure (COPP) is defined as the variations in diastolic OPP during the day and night. Diastolic ocular perfusion pressure was calculated at 7 timepoints over a 24-hour period. Changes in the diastolic ocular perfusion pressure rhythm throughout the day (outside the normal range) may affect glaucoma progression.

    Time frame: Week 0, Week 6 (period-based)

  2. Mean Change From Baseline in Mean Flow Value in the Superotemporal Peripapillary Retina at Week 6

    Retinal perfusion assessments were made using Heidelberg Retinal Flowmetry (HRF). Assessments were made at 4 timepoints over a 12-hour period. Intensity of blood flow was measured in arbitrary units, with a higher number indicating an increased blood flow. An increase in ocular blood flow may reduce the risk of glaucoma progression.

    Time frame: Week 0, Week 6 (period-based)

  3. Mean Change From Baseline in Mean Flow Value in the Inverotemporal Peripapillary Retina at Week 6

    Retinal perfusion assessments were made using Heidelberg Retinal Flowmetry (HRF). Assessments were made at 4 timepoints over a 12-hour period. Intensity of blood flow was measured in arbitrary units, with a higher number indicating an increased blood flow. An increase in ocular blood flow may reduce the risk of glaucoma progression.

    Time frame: Week 0, Week 6 (period-based)

  4. Mean Change From Baseline in Intraocular Pressure (IOP) at Week 6

    Intraocular pressure (IOP) is defined as the fluid pressure inside the eye. Intraocular pressure was measured with a calibrated pneumatonometer at 7 time points over a 24-hour period. High IOP (outside the normal range) can be a risk factor for developing glaucoma or glaucoma progression (leading to optic nerve damage).

    Time frame: Week 0, Week 6 (period-based)

  5. Mean Change From Baseline in Diastolic Blood Pressure at Week 6

    Blood pressure is defined as the pressure exerted by circulating blood upon the walls of the blood vessels, that is, arterial pressure of the systemic circulation of blood. Diastolic blood pressure refers to the minimum pressure, that is, the pressure between heartbeats. Diastolic glood pressure was measured at 7 timepoints in a 24-hour period using a calibrated sphygmomonometer. Higher blood pressure (outside the normal range) can be a risk factor for developing cardiovascular events, such as heart attack, stroke, or heart failure. Lower blood pressure (outside the normal range) can be a risk factor for dizziness or fainting.

    Time frame: Week 0, Week 6 (period-based)

  6. Mean Change From Baseline in Systolic Blood Pressure at Week 6

    Blood pressure is defined as the pressure exerted by circulating blood upon the walls of the blood vessels, that is, arterial pressure of the systemic circulation of blood. Systolic blood pressure refers to the maximum pressure, that is, the pressure while the heart is beating, and was measured at 7 timepoints in a 24-hour period using a calibrated sphygmomonometer. Higher blood pressure (outside the normal range) can be a risk factor for developing cardiovascular events, such as heart attack, stroke, or heart failure. Lower blood pressure (outside the normal range) can be a risk factor for dizziness or fainting.

    Time frame: Week 0, Week 6 (period-based)

  7. Mean Change From Baseline in Vascular Resistance in the Central Retinal Artery at Week 6

    Vascular resistance in the central retinal artery was assessed using Color Doppler Imaging (CDI). Assessments were made at 7 time points over a 24-hour period.

    Time frame: Week 0, Week 6 (period-based)

  8. Mean Change From Baseline in Vascular Resistance in the Ophthalmic Artery at 6 Weeks

    Vascular resistance in the ophthalmic artery was assessed using Color Doppler Imaging (CDI). Assessments were made at 7 time points over a 24-hour period.

    Time frame: Week 0, Week 6 (period-based)

  9. Mean Change From Baseline in End Diastolic Velocity in the Ophthalmic Artery at Week 6

    End diastolic velocity in the ophthalmic artery was assessed using Color Doppler Imaging (CDI). Assessments were made at 7 time points over a 24-hour period.

    Time frame: Week 0, Week 6 (period-based)

  10. Mean Change From Baseline in Peak Systolic Velocity in the Ophthalmic Artery at Week 6

    Peak systolic velocity in the ophthalmic artery was assessed using Color Doppler Imaging (CDI). Assessments were made at 7 time points over a 24-hour period.

    Time frame: Week 0, Week 6 (period-based)

  11. Mean Change From Baseline in Peak Systolic Velocity in the Central Retinal Artery at Week 6

    Peak systolic velocity in the central retinal artery was assessed using Color Doppler Imaging (CDI). Assessments were made at 7 time points over a 24-hour period.

    Time frame: Week 0, Week 6 (period-based)

07

Results

Posted Mar 22, 2013

Participant flow

Participants were recruited from and enrolled at one study center located in Greece.

Period One: 6 Weeks
Participant flow — Period One: 6 Weeks
MilestoneAZARGA/COMBIGANCOMBIGAN/AZARGA
Started1718
Completed1617
Not completed11
Withdrew: Noncompliance10
Withdrew: Pt decision unrelated to adverse event01
Washout: 4 Weeks
Participant flow — Washout: 4 Weeks
MilestoneAZARGA/COMBIGANCOMBIGAN/AZARGA
Started1617
Completed1617
Not completed00
Period 2: 6 Weeks
Participant flow — Period 2: 6 Weeks
MilestoneAZARGA/COMBIGANCOMBIGAN/AZARGA
Started1617
Completed1616
Not completed01
Withdrew: Adverse event01

Outcome measures

PrimaryMean Change From Baseline in Overall Diastolic Ocular Perfusion Pressure at Week 6

Diastolic ocular perfusion pressure (DOPP) is defined as the difference between diastolic arterial pressure and intraocular pressure. Diastolic arterial pressure was measured with a calibrated automated sphygmomanometer. Intraocular pressure was measured with a calibrated pneumatonometer. A lower DOPP indicates a lower optic blood supply, which can be a risk factor for developing glaucoma or glaucoma progression (leading to optic nerve damage).

Time frame:
Week 0, Week 6 (period-based)
Reported as:
Mean · mmHg (millimeters of mercury)
Mean Change From Baseline in Overall Diastolic Ocular Perfusion Pressure at Week 6
mmHg (millimeters of mercury)AZARGACOMBIGAN
Mean Change From Baseline in Overall Diastolic Ocular Perfusion Pressure at Week 62.6 ± 0.7800.8 ± 0.779
SecondaryMean Change From Baseline in Circadian Diastolic Ocular Perfusion Pressure at Week 6

Circadian diastolic ocular perfusion pressure (COPP) is defined as the variations in diastolic OPP during the day and night. Diastolic ocular perfusion pressure was calculated at 7 timepoints over a 24-hour period. Changes in the diastolic ocular perfusion pressure rhythm throughout the day (outside the normal range) may affect glaucoma progression.

Time frame:
Week 0, Week 6 (period-based)
Reported as:
Mean · mmHg (millimeters of mercury)
Mean Change From Baseline in Circadian Diastolic Ocular Perfusion Pressure at Week 6
mmHg (millimeters of mercury)AZARGACOMBIGAN
9:00 am2.8 ± 1.2826.5 ± 1.282
1:00 pm3.0 ± 1.2822.1 ± 1.282
5:00 pm4.4 ± 1.2823.9 ± 1.282
9:00 pm4.5 ± 1.2822.0 ± 1.282
12:00 am0.8 ± 1.282-5.6 ± 1.282
3:00 am0.3 ± 1.282-4.0 ± 1.282
6:00 am2.0 ± 1.2960.9 ± 1.282
SecondaryMean Change From Baseline in Mean Flow Value in the Superotemporal Peripapillary Retina at Week 6

Retinal perfusion assessments were made using Heidelberg Retinal Flowmetry (HRF). Assessments were made at 4 timepoints over a 12-hour period. Intensity of blood flow was measured in arbitrary units, with a higher number indicating an increased blood flow. An increase in ocular blood flow may reduce the risk of glaucoma progression.

Time frame:
Week 0, Week 6 (period-based)
Reported as:
Mean · Arbitrary Units
Mean Change From Baseline in Mean Flow Value in the Superotemporal Peripapillary Retina at Week 6
Arbitrary UnitsAZARGACOMBIGAN
9:00 am-272.4 ± 146.294-43.5 ± 146.586
1:00 pm-12.1 ± 142.844248.9 ± 144.917
5:00 pm-26.7 ± 144.914-51.3 ± 142.844
9:00 pm14.0 ± 148.317-33.2 ± 144.451
SecondaryMean Change From Baseline in Mean Flow Value in the Inverotemporal Peripapillary Retina at Week 6

Retinal perfusion assessments were made using Heidelberg Retinal Flowmetry (HRF). Assessments were made at 4 timepoints over a 12-hour period. Intensity of blood flow was measured in arbitrary units, with a higher number indicating an increased blood flow. An increase in ocular blood flow may reduce the risk of glaucoma progression.

Time frame:
Week 0, Week 6 (period-based)
Reported as:
Mean · Arbitrary Units
Mean Change From Baseline in Mean Flow Value in the Inverotemporal Peripapillary Retina at Week 6
Arbitrary UnitsAZARGACOMBIGAN
9:00 am15.9 ± 92.064-70.0 ± 89.642
1:00 pm-40.7 ± 89.642-89.2 ± 95.324
5:00 pm-38.7 ± 88.363-69.1 ± 92.610
9:00 pm182.3 ± 92.064-91.0 ± 92.064
SecondaryMean Change From Baseline in Intraocular Pressure (IOP) at Week 6

Intraocular pressure (IOP) is defined as the fluid pressure inside the eye. Intraocular pressure was measured with a calibrated pneumatonometer at 7 time points over a 24-hour period. High IOP (outside the normal range) can be a risk factor for developing glaucoma or glaucoma progression (leading to optic nerve damage).

Time frame:
Week 0, Week 6 (period-based)
Reported as:
Mean · mmHg (millimeters of mercury)
Mean Change From Baseline in Intraocular Pressure (IOP) at Week 6
mmHg (millimeters of mercury)AZARGACOMBIGAN
9:00 am-6.3 ± 0.661-6.5 ± 0.661
1:00 pm-6.0 ± 0.661-6.5 ± 0.661
5:00 pm-5.6 ± 0.661-5.2 ± 0.661
9:00 pm-4.3 ± 0.661-4.9 ± 0.661
12:00 am-1.9 ± 0.661-1.6 ± 0.661
3:00 am-1.3 ± 0.661-0.6 ± 0.661
6:00 am-2.3 ± 0.668-1.2 ± 0.661
SecondaryMean Change From Baseline in Diastolic Blood Pressure at Week 6

Blood pressure is defined as the pressure exerted by circulating blood upon the walls of the blood vessels, that is, arterial pressure of the systemic circulation of blood. Diastolic blood pressure refers to the minimum pressure, that is, the pressure between heartbeats. Diastolic glood pressure was measured at 7 timepoints in a 24-hour period using a calibrated sphygmomonometer. Higher blood pressure (outside the normal range) can be a risk factor for developing cardiovascular events, such as heart attack, stroke, or heart failure. Lower blood pressure (outside the normal range) can be a risk factor for dizziness or fainting.

Time frame:
Week 0, Week 6 (period-based)
Reported as:
Mean · mmHg (millimeters of mercury)
Mean Change From Baseline in Diastolic Blood Pressure at Week 6
mmHg (millimeters of mercury)AZARGACOMBIGAN
9:00 am-3.3 ± 1.3150.6 ± 1.315
1:00 pm-3.5 ± 1.315-4.3 ± 1.315
5:00 pm-1.5 ± 1.315-0.9 ± 1.315
9:00 pm-0.5 ± 1.315-2.1 ± 1.315
12:00 am-1.4 ± 1.315-7.3 ± 1.315
3:00 am-1.5 ± 1.315-3.8 ± 1.315
6:00 am-0.5 ± 1.334-0.7 ± 1.315
SecondaryMean Change From Baseline in Systolic Blood Pressure at Week 6

Blood pressure is defined as the pressure exerted by circulating blood upon the walls of the blood vessels, that is, arterial pressure of the systemic circulation of blood. Systolic blood pressure refers to the maximum pressure, that is, the pressure while the heart is beating, and was measured at 7 timepoints in a 24-hour period using a calibrated sphygmomonometer. Higher blood pressure (outside the normal range) can be a risk factor for developing cardiovascular events, such as heart attack, stroke, or heart failure. Lower blood pressure (outside the normal range) can be a risk factor for dizziness or fainting.

Time frame:
Week 0, Week 6 (period-based)
Reported as:
Mean · mmHg (millimeters of mercury)
Mean Change From Baseline in Systolic Blood Pressure at Week 6
mmHg (millimeters of mercury)AZARGACOMBIGAN
9:00 am-4.2 ± 2.1344.5 ± 2.134
1:00 pm-2.6 ± 2.134-1.9 ± 2.134
5:00 pm-2.9 ± 2.134-0.4 ± 2.134
9:00 pm-1.4 ± 2.134-0.6 ± 2.134
12:00 am-2.9 ± 2.134-12.2 ± 2.134
3:00 am-2.9 ± 2.134-3.0 ± 2.134
6:00 am-0.1 ± 2.1653.0 ± 2.134
SecondaryMean Change From Baseline in Vascular Resistance in the Central Retinal Artery at Week 6

Vascular resistance in the central retinal artery was assessed using Color Doppler Imaging (CDI). Assessments were made at 7 time points over a 24-hour period.

Time frame:
Week 0, Week 6 (period-based)
Reported as:
Mean · cm/s (centimeters per second)
Mean Change From Baseline in Vascular Resistance in the Central Retinal Artery at Week 6
cm/s (centimeters per second)AZARGACOMBIGAN
9:00 am-0.00 ± 0.0140.01 ± 0.014
1:00 pm-0.01 ± 0.0140.01 ± 0.014
5:00 pm0.00 ± 0.014-0.00 ± 0.014
9:00 pm0.00 ± 0.0140.02 ± 0.014
12:00 am0.02 ± 0.014-0.01 ± 0.014
3:00 am0.01 ± 0.0140.01 ± 0.014
6:00 am-0.02 ± 0.0140.02 ± 0.014
SecondaryMean Change From Baseline in Vascular Resistance in the Ophthalmic Artery at 6 Weeks

Vascular resistance in the ophthalmic artery was assessed using Color Doppler Imaging (CDI). Assessments were made at 7 time points over a 24-hour period.

Time frame:
Week 0, Week 6 (period-based)
Reported as:
Mean · cm/s (centimeters per second)
Mean Change From Baseline in Vascular Resistance in the Ophthalmic Artery at 6 Weeks
cm/s (centimeters per second)AZARGACOMBIGAN
9:00 am-0.01 ± 0.012-0.01 ± 0.011
1:00 pm0.02 ± 0.0120.02 ± 0.012
5:00 pm0.01 ± 0.0120.01 ± 0.012
9:00 pm0.01 ± 0.0120.01 ± 0.011
12:00 am-0.01 ± 0.0120.02 ± 0.012
3:00 am0.01 ± 0.0120.03 ± 0.012
6:00 am0.01 ± 0.0120.03 ± 0.011
SecondaryMean Change From Baseline in End Diastolic Velocity in the Ophthalmic Artery at Week 6

End diastolic velocity in the ophthalmic artery was assessed using Color Doppler Imaging (CDI). Assessments were made at 7 time points over a 24-hour period.

Time frame:
Week 0, Week 6 (period-based)
Reported as:
Mean · cm/s (centimeters per second)
Mean Change From Baseline in End Diastolic Velocity in the Ophthalmic Artery at Week 6
cm/s (centimeters per second)AZARGACOMBIGAN
9:00 am-0.0 ± 0.454-0.8 ± 0.448
1:00 pm-0.6 ± 0.459-1.2 ± 0.460
5:00 pm0.5 ± 0.4590.2 ± 0.466
9:00 pm0.4 ± 0.454-0.8 ± 0.448
12:00 am-0.8 ± 0.466-1.4 ± 0.454
3:00 am-0.1 ± 0.454-0.6 ± 0.459
6:00 am-0.2 ± 0.466-0.5 ± 0.448
SecondaryMean Change From Baseline in Peak Systolic Velocity in the Ophthalmic Artery at Week 6

Peak systolic velocity in the ophthalmic artery was assessed using Color Doppler Imaging (CDI). Assessments were made at 7 time points over a 24-hour period.

Time frame:
Week 0, Week 6 (period-based)
Reported as:
Median · cm/s (centimeters per second)
Mean Change From Baseline in Peak Systolic Velocity in the Ophthalmic Artery at Week 6
cm/s (centimeters per second)AZARGACOMBIGAN
9:00 am-1.0 ± 1.237-3.8 ± 1.221
1:00 pm-0.7 ± 1.251-1.4 ± 1.254
5:00 pm2.2 ± 1.2511.3 ± 1.267
9:00 pm2.2 ± 1.237-1.4 ± 1.221
12:00 am-2.3 ± 1.268-3.1 ± 1.235
3:00 am0.2 ± 1.2350.0 ± 1.250
6:00 am-0.6 ± 1.2671.5 ± 1.221
SecondaryMean Change From Baseline in Peak Systolic Velocity in the Central Retinal Artery at Week 6

Peak systolic velocity in the central retinal artery was assessed using Color Doppler Imaging (CDI). Assessments were made at 7 time points over a 24-hour period.

Time frame:
Week 0, Week 6 (period-based)
Reported as:
Mean · cm/s (centimeters per second)
Mean Change From Baseline in Peak Systolic Velocity in the Central Retinal Artery at Week 6
cm/s (centimeters per second)AZARGACOMBIGAN
9:00 am0.9 ± 0.5710.7 ± 0.565
1:00 pm-0.2 ± 0.5770.3 ± 0.578
5:00 pm1.0 ± 0.5770.6 ± 0.565
9:00 pm0.9 ± 0.565-0.5 ± 0.565
12:00 am1.9 ± 0.577-0.5 ± 0.565
3:00 am0.2 ± 0.565-1.1 ± 0.570
6:00 am0.2 ± 0.5710.9 ± 0.565

Adverse events

Collected over Adverse events were collected for the duration of the study.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AZARGA—1/34 (2.9%)0/34 (0%)
COMBIGAN—0/34 (0%)0/34 (0%)
Most frequent serious events
Most frequent serious events
EventAZARGACOMBIGAN
Breast CancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/340/34

Baseline characteristics

This reporting group includes all enrolled participants.

Age Continuous
Age Continuous(years)Overall
Mean65.2 ± 10.3
Sex: Female, Male
Sex: Female, Male(Participants)Overall
Female19
Male16
Region of Enrollment
Region of Enrollment(participants)Overall
Greece35
08

Study locations

1 site
  • Contact Alcon Call Center at 1-888-451-3937 For Trial Locations
    Fort Worth, Texas 76134, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2009, a primary completion of Jan 2012 and a completion of Jan 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2013, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2008
First posted
Dec 2, 2008
Start
Feb 2009
Primary completionActual
Jan 2012
CompletionActual
Jan 2012
Results first posted
Mar 22, 2013
Last update
Mar 22, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 22, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00800540
Lead sponsor
Alcon Research
Responsible party
Sponsor
First posted
Dec 2, 2008
Start date
Feb 2009
Primary completion
Jan 2012
Completion
Jan 2012
Results posted
Mar 22, 2013
Last update
Mar 22, 2013

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Brinzolamide · Brimonidine

Start the discussion